These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
145 related items for PubMed ID: 17062689
21. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH. Clin Cancer Res; 1998 Oct; 4(10):2293-7. PubMed ID: 9796957 [Abstract] [Full Text] [Related]
22. Differential involvement of multidrug resistance-associated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y. J Pharmacol Exp Ther; 2004 Aug; 310(2):648-55. PubMed ID: 15131241 [Abstract] [Full Text] [Related]
23. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Pajic M, Iyer JK, Kersbergen A, van der Burg E, Nygren AO, Jonkers J, Borst P, Rottenberg S. Cancer Res; 2009 Aug 15; 69(16):6396-404. PubMed ID: 19654309 [Abstract] [Full Text] [Related]
25. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM. Cancer Chemother Pharmacol; 2008 Nov 15; 62(6):1045-54. PubMed ID: 18301895 [Abstract] [Full Text] [Related]
26. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. van Asperen J, van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH. Br J Cancer; 1999 Jan 15; 79(1):108-13. PubMed ID: 10408701 [Abstract] [Full Text] [Related]
27. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY, Rooswinkel RW, van Tellingen O, Rosing H, Beijnen JH, Schinkel AH. Cancer Res; 2009 Dec 01; 69(23):8996-9002. PubMed ID: 19920203 [Abstract] [Full Text] [Related]
30. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. Iusuf D, Teunissen SF, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. J Pharmacol Exp Ther; 2011 Jun 01; 337(3):710-7. PubMed ID: 21378205 [Abstract] [Full Text] [Related]
31. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats. Lee CK, Choi JS. Pharmacology; 2010 Jun 01; 85(6):350-6. PubMed ID: 20523105 [Abstract] [Full Text] [Related]
34. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats. Choi BC, Choi JS, Han HK. Int J Pharm; 2006 Oct 12; 323(1-2):81-5. PubMed ID: 16806758 [Abstract] [Full Text] [Related]
35. Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats. Jin J, Bi H, Hu J, Zhong G, Zhao L, Huang Z, Huang M. Biopharm Drug Dispos; 2010 May 12; 31(4):264-8. PubMed ID: 20437465 [Abstract] [Full Text] [Related]
39. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. J Clin Invest; 1995 Oct 12; 96(4):1698-705. PubMed ID: 7560060 [Abstract] [Full Text] [Related]